Summary of CapsoVision Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $3.6 million, a 10% increase from $3.3 million in Q2 2025.

Capsules Sold: 8,845 CapsoCam Plus capsules shipped, up approximately 13% year-over-year.

Gross Profit: $1.9 million, with a gross margin of 51%, down from 55% in the prior year due to pricing pressures and increased customs/tariff costs.

Operating Expenses: $9.5 million, up from $6.5 million in Q2 2025, reflecting investments in product development and clinical trials.

Cash Position: $9.1 million in cash and equivalents; raised $14 million in Q1 2026 and established a $100 million at-the-market equity offering program.

2Strategic Updates and Business Highlights

Revenue Growth: Achieved 10% year-over-year growth, driven by increased adoption of the CapsoCam Plus platform.

Patient Imaging: Over 176,000 patients imaged with CapsoCam Plus, a 23% increase from the previous year.

AI Highlights Launch: Successfully launched AI Highlights in the EU and other international markets, enhancing the AI-enabled platform for capsule endoscopy.

Regulatory Progress: Working towards FDA clearance for AI Highlights, with expectations for approval by the end of Q3 2026.

Product Pipeline: Advancements in CapsoCam Colon and ongoing clinical studies for pancreatic cancer detection.

3Forward Guidance and Outlook

Second Half Expectations: Anticipate stronger revenue in the second half of 2026 compared to the first half, driven by the U.S. launch of AI Highlights and continued commercial momentum.

Growth Strategy: Focus on expanding the commercial footprint and advancing the product pipeline, particularly with CapsoCam Colon and other diagnostic applications.

4Bad News, Challenges, or Points of Concern

Pricing Pressure: Noted competitive pressures affecting pricing, particularly from one competitor, which has impacted margins.

Tariff Impact: Increased customs and tariff expenses affecting gross margins.

Operating Losses: Operating expenses have risen significantly, leading to ongoing losses as the company invests in growth.

FDA Approval Risks: Uncertainty regarding FDA clearance for AI Highlights, as demographic representation in clinical data is under review.

5Notable Q&A Insights

Pricing Pressure Sources: Competitive influences and cost-consciousness among hospitals were identified as sources of pricing pressure.

Sales Force Strategy: Current sales force of 26 representatives and 7 regional managers is deemed sufficient for now, with plans for gradual expansion as new products are introduced.

AI Highlights Feedback: Early customer feedback on AI Highlights has been positive, with expectations that it will drive broader adoption of capsule endoscopy.

Seasonality in Sales: The fourth quarter is expected to be stronger than the third, consistent with historical trends in the business. This summary encapsulates the key points from CapsoVision's Q2 2026 earnings call, highlighting both achievements and challenges faced by the company.